{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-109439","form_type":"8-K","ticker":"VSTM","cik":"0001526119","company_name":"Verastem, Inc.","filed_at":"2024-10-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.687547+00:00","generated_at":"2026-05-30T13:17:57.174273+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Verastem reports 31% ORR with avutometinib/defactinib in RAMP 201; NDA submission ongoing","bullets":["Confirmed ORR of 31% overall (44% KRAS mutant, 17% KRAS wild type) by BICR.","Median duration of response 31.1 months; median PFS 12.9 months overall.","Discontinuation rate due to AEs was 10%; safety manageable with dose modifications.","Low-dose regimen (1.6 mg avutometinib) suboptimal; 22% progressed within 4 months vs 12% at 3.2 mg.","Rolling NDA submission to FDA for avutometinib+defactinib in recurrent LGSOC is underway."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-109439","json":"https://secwatch.observer/filing/0001104659-24-109439.json","markdown":"https://secwatch.observer/filing/0001104659-24-109439.md","text":"https://secwatch.observer/filing/0001104659-24-109439.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1526119/000110465924109439/0001104659-24-109439-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1526119/000110465924109439/tm2426322d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T13:17:57.174273+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}